Published in Biochemistry on September 19, 1989
Regulation of receptor binding affinity of influenza virus hemagglutinin by its carbohydrate moiety. J Virol (1997) 2.09
Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein. Biochem J (1992) 0.99
Increased productivity of recombinant tissular plasminogen activator (t-PA) by butyrate and shift of temperature: a cell cycle phases analysis. Cytotechnology (2001) 0.98
Carbohydrate analysis throughout the development of a protein therapeutic. Glycoconj J (2009) 0.97
In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells. Proc Natl Acad Sci U S A (1999) 0.93
Asn and asn: critical residues for in vitro biological activity of reteplase. Adv Hematol (2010) 0.92
Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen activator. Anal Chem (2010) 0.88
Separation and characterization of the two Asn-linked glycosylation sites of chicken serum riboflavin-binding protein. Glycosylation differences despite similarity of primary structure. Biochem J (1992) 0.78
Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein. J Clin Invest (1990) 0.78
Gastric and salivary mucins inhibit angiotensin-converting enzyme. Inhibition is partly due to oligosaccharides. Biochem J (1992) 0.75
The glycosylation of Bowes melanoma tissue plasminogen activator: lectin mapping, reaction with anti-L2/HNK-1 antibodies and the presence of sulphated/glucuronic acid containing glycans. Biochem J (1996) 0.75
Binding of tissue plasminogen activator to human aortic endothelial cells. Biochem J (1990) 0.75
Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases. Int J Mol Sci (2016) 0.75
Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature (2002) 19.35
The genome sequence of Schizosaccharomyces pombe. Nature (2002) 14.26
Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (1989) 8.10
Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science (2001) 5.39
Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature (1985) 5.32
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA (1999) 4.91
Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. Infect Immun (1995) 4.58
Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA (2001) 4.54
Glycobiology. Annu Rev Biochem (1988) 4.51
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med (2000) 4.39
Glycosylation and the immune system. Science (2001) 4.39
Glycosyl-phosphatidylinositol moiety that anchors Trypanosoma brucei variant surface glycoprotein to the membrane. Science (1988) 3.41
Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med (1995) 3.38
Accidental middle turbinectomy: a complication of nasal intubation. Anesthesiology (1999) 2.96
Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature (2001) 2.78
Concepts and principles of O-linked glycosylation. Crit Rev Biochem Mol Biol (1998) 2.66
Locations and contexts of sequences that hybridize to poly(dG-dT).(dC-dA) in mammalian ribosomal DNAs and two X-linked genes. Nucleic Acids Res (1988) 2.64
Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol (1979) 2.53
A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal Biochem (1996) 2.44
Glycosylation: heterogeneity and the 3D structure of proteins. Crit Rev Biochem Mol Biol (1997) 2.36
Stimulus control of temporally spaced responding in second-order schedules. J Exp Anal Behav (1967) 2.20
Complete structure of the glycosyl phosphatidylinositol membrane anchor of rat brain Thy-1 glycoprotein. Nature (1988) 2.17
Sequencing of N-linked oligosaccharides directly from protein gels: in-gel deglycosylation followed by matrix-assisted laser desorption/ionization mass spectrometry and normal-phase high-performance liquid chromatography. Anal Biochem (1997) 2.12
The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions. J Biol Chem (1998) 2.10
Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na(+)] and pH but elevated viscosity. Proc Natl Acad Sci U S A (2001) 2.10
N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem (1994) 2.05
Raster image correlation spectroscopy (RICS) for measuring fast protein dynamics and concentrations with a commercial laser scanning confocal microscope. J Microsc (2008) 2.04
The high degree of internal flexibility observed for an oligomannose oligosaccharide does not alter the overall topology of the molecule. Eur J Biochem (1998) 2.00
A proenzyme form of human urokinase. J Biol Chem (1982) 1.98
Conservation of 70S ribosomal RNA genes in the chloroplast DNAs of higher plants. Proc Natl Acad Sci U S A (1974) 1.95
Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J (1990) 1.87
Characterization of a rabbit model of staphylococcal osteomyelitis. J Orthop Res (1997) 1.86
Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain (2003) 1.82
cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta. J Biol Chem (1987) 1.79
Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology (2001) 1.75
Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proc Natl Acad Sci U S A (1988) 1.75
Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science (1997) 1.70
Some factors controlling preference between fixed-ratio and variable-ratio schedules of reinforcement. J Exp Anal Behav (1968) 1.68
Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor. Mol Immunol (1985) 1.68
A statistical analysis of N- and O-glycan linkage conformations from crystallographic data. Glycobiology (1999) 1.67
Risk factors for surgical-wound infection following cardiac surgery. J Infect Dis (1987) 1.66
Tissue-specific N-glycosylation, site-specific oligosaccharide patterns and lentil lectin recognition of rat Thy-1. EMBO J (1987) 1.66
Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A (1994) 1.66
Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc Natl Acad Sci U S A (1994) 1.65
Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol (2001) 1.65
Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med (1998) 1.64
Structure, biosynthesis, and function of glycosylphosphatidylinositols. Biochemistry (1990) 1.63
Glycosylation differences between the normal and pathogenic prion protein isoforms. Proc Natl Acad Sci U S A (1999) 1.60
The glycosylation of the influenza A virus hemagglutinin by mammalian cells. A site-specific study. J Biol Chem (1997) 1.58
Conformation-independent binding of monoglucosylated ribonuclease B to calnexin. Cell (1997) 1.58
Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc Natl Acad Sci U S A (1999) 1.54
Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A (1999) 1.53
Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem (1990) 1.52
Influence of a steroid receptor DNA-binding domain on transcriptional regulatory functions. Genes Dev (1994) 1.52
Glycoproteins: glycan presentation and protein-fold stability. Structure (1999) 1.51
Isolation and characterization of urokinase from human plasma. J Biol Chem (1982) 1.47
N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol (2000) 1.47
Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation (1991) 1.47
Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc Natl Acad Sci U S A (1997) 1.46
Effect of botulinum toxin pretreatment on laser resurfacing results: a prospective, randomized, blinded trial. Arch Facial Plast Surg (2001) 1.46
I-E-independent deletion of V beta 17a+ T cells by Mtv-3 from the nonobese diabetic mouse. J Immunol (1992) 1.46
Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet (1988) 1.46
Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood (1992) 1.46
Intracellular receptors use a common mechanism to interpret signaling information at response elements. Genes Dev (1996) 1.46
Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry (1997) 1.46
N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120. J Virol (1996) 1.46
The beta 1----2-D-xylose and alpha 1----3-L-fucose substituted N-linked oligosaccharides from Erythrina cristagalli lectin. Isolation, characterisation and comparison with other legume lectins. Eur J Biochem (1987) 1.45
Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis (2004) 1.45
Transplantation tolerance in adult rats using total lymphoid irradiation: permanent survival of skin, heart, and marrow allografts. J Exp Med (1978) 1.44
Aberrant control of galactosyltransferase in peripheral B lymphocytes and Epstein-Barr virus transformed B lymphoblasts from patients with rheumatoid arthritis. J Rheumatol (1993) 1.43
Characterization of the cross-reacting determinant (CRD) of the glycosyl-phosphatidylinositol membrane anchor of Trypanosoma brucei variant surface glycoprotein. Eur J Biochem (1988) 1.43
The mechanism of water-proton relaxation in enzyme paramagnetic-ion complexes. 1. The Gd(3)-lysozyme complex. Eur J Biochem (1974) 1.42
Staphylococcus aureus collagen adhesin contributes to the pathogenesis of osteomyelitis. Bone (2002) 1.40
The Clq receptor site on immunoglobulin G. Nature (1980) 1.40
Violence in America: an issue of public health. Mo Med (1993) 1.39
Boxing and the fight to ban it. Mo Med (1999) 1.39
Effects of the imino sugar N-butyldeoxynojirimycin on the N-glycosylation of recombinant gp120. J Biol Chem (1993) 1.36
Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A (1994) 1.35
Glycoforms modify the dynamic stability and functional activity of an enzyme. Biochemistry (1994) 1.34
Alpha-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Lett (1998) 1.32